非小细胞肺癌中奥希替尼耐药机制及应对策略的研究进展

Progress of mechanisms of osimertinib resistance and coping strategies in non-small cell lung cancer

奥希替尼作为第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),在携带EGFR突变的非小细胞肺癌(NSCLC)患者的靶向治疗中取得了显著的临床效益,但其耐药不可避免。为了应对奥希替尼的药物抵抗,新一代靶向药物的研发及相应的治疗策略也在发展中,并有部分已进入临床试验。文章主要对奥希替尼的耐药机制及其耐药后治疗策略的研究进展进行综述。

Osimertinib,the third generation of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),has demonstrated notable clinical benefit in the targeted therapy for patients with non-small cell lung cancer(NSCLC).However,the development of drug resistance is an inevitable challenge.In order to tackle this issue,ongoing efforts are being made to develop new generations of targeted drugs and treatment strategies,some of which are already undergoing clinical trials.This article aims to review the current research on the mechanisms of osimertinib resistance and outline the advancements made in post-drug resistance treatment strategies.